Cytek Biosciences (CTKB) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Stephens & Co. | Maintained | Overweight | $4.75 from $5.50 | May 13, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $5.50 from $6.00 | May 12, 2026 |
| TD Cowen | Maintained | Buy | $5.00 from $4.00 | Jan 8, 2026 |
| Piper Sandler | Maintained | Overweight | $7.50 from $8.00 | Nov 11, 2025 |
| Morgan Stanley | Maintained | Equal-Weight | $7.00 from $9.00 | May 28, 2025 |
| Goldman Sachs | Maintained | Sell | $3.00 from $3.50 | May 12, 2025 |
| Stephens & Co. | Maintained | Overweight | $6.00 | Mar 19, 2025 |
| Piper Sandler | Maintained | Overweight | $8.00 from $8.50 | Mar 4, 2025 |
| Piper Sandler | Maintained | Overweight | $8.50 from $8.00 | Nov 11, 2024 |
| Piper Sandler | Maintained | Overweight | $8.00 from $8.50 | Aug 13, 2024 |
| Piper Sandler | Maintained | Overweight | $8.50 from $10.00 | May 13, 2024 |
| Piper Sandler | Maintained | Overweight | $10.00 from $11.00 | Mar 6, 2024 |
| Goldman Sachs | Maintained | Buy | $10.00 from $9.00 | Feb 29, 2024 |
| Stephens & Co. | Initiated Coverage | Overweight | $9.00 | Dec 14, 2023 |
| Morgan Stanley | Maintained | Equal-Weight | $7.00 from $8.00 | Nov 9, 2023 |
| Morgan Stanley | Maintained | Equal-Weight | $8.00 from $13.00 | Oct 24, 2023 |
| Piper Sandler | Maintained | Overweight | $10.00 from $15.00 | Oct 16, 2023 |
| Raymond James | Initiated Coverage | Market Perform | — | Jul 19, 2023 |
| Morgan Stanley | Maintained | Equal-Weight | $13.00 from $14.00 | May 11, 2023 |
| Goldman Sachs | Maintained | Buy | $12.00 from $14.00 | May 10, 2023 |
Frequently asked questions
Is CTKB a buy, sell, or hold?
Analysts covering Cytek Biosciences currently average a Buy rating: 2 buy, 2 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CTKB?
On May 13, 2026, Stephens & Co. maintained Cytek Biosciences at Overweight with a price target of $4.75.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.